CTI adds CAD to PET/CT
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
The Reveal PET/CT system merges PET and CT technologies to generate functional and anatomical data in a single scan, which improves the localization of metabolic hot spots for cancer staging.
FDG, the active metabolite of PET scanning, accumulates not only in disease sites, but also in areas of inflammation and infection. The addition of CAD to the Reveal PET/CT system helps decipher inflammatory isotope uptake from metabolic localization of true malignant pathology so infection or inflammation in the pleural lining will not be mistaken for lung cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
